Geode Capital Management
CNSP icon

Geode Capital Management’s CNS Pharmaceuticals CNSP Stock Holding History

Geode Capital Management’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,189
Closed -$55.7K – 4469
2026
Q1 		$55.7K Buy
+23,189
New +$96.1K ﹤0.01% 4287
2025
Q3 		– Sell
-1,489
Closed -$14.7K – 4492
2025
Q2 		$14.7K Buy
+1,489
New +$18.6K ﹤0.01% 4396
2025
Q1 		– Sell
-645
Closed -$46.6K – 4486
2024
Q4 		$46.6K Buy
645
+306
+90% +$21.8K ﹤0.01% 4254
2024
Q3 		$26.5K Buy
+339
New +$97.2K ﹤0.01% 4367
2024
Q2 		– Sell
-1
Closed -$10.2K – 4593
2024
Q1 		$10.2K Hold
1
– – ﹤0.01% 4551
2023
Q4 		$30.8K Hold
1
– – ﹤0.01% 4449
2023
Q3 		$27.4K Hold
1
– – ﹤0.01% 4561
2023
Q2 		$36K Buy
+1
New +$53.7K ﹤0.01% 4573
2022
Q4 		– Hold
0
– -$23K – 4904
2022
Q3 		– Hold
0
– – – 4894
2022
Q2 		– Hold
0
– – – 4846
2022
Q1 		– Hold
0
– – – 4830
2021
Q4 		– Hold
0
– – – 4792
2021
Q3 		– Hold
0
– – – 4525
2021
Q2 		– Hold
0
– – – 4349
2021
Q1 		– Hold
0
– – – 4210

Other funds holding CNSP

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return

Geode Capital Management's CNSP Position: Q2 2026 in Review

Geode Capital Management sold out of CNS Pharmaceuticals (CNSP) in Q2 2026, closing a stake of 23,189 shares — an estimated $55.7K sold.

Geode Capital Management first reported a position in CNSP in Q2 2023 and held it in 8 quarters. The position peaked at $55.7K in Q1 2026. 11 funds tracked by Wall St. Rank hold CNSP as of Q2 2026.

  • Geode Capital Management reported no remaining CNS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Geode Capital Management sold 23,189 CNS Pharmaceuticals shares in Q2 2026, an estimated $55.7K.
  • Geode Capital Management first reported a position in CNS Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Geode Capital Management's CNS Pharmaceuticals position peaked at $55.7K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.